Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Search in:

Advanced search

Vascular Health and Risk Management Volume 16, 2020 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Review

Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects

Daniel A Duprez1 Cardiovascular Division, School of Medicine, University of Minnesota, Minneapolis, MN, USACorrespondence[email protected]
View further author information

Yehuda Handelsman2 Metabolic Institute of America, Tarzana, CA, USA

https://orcid.org/0000-0001-7830-0247 View further author information

Michael Koren3 Jacksonville Center for Clinical Research, Jacksonville, FL, USAView further author information

Pages 403-418 | Published online: 07 Oct 2020

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (3)

Dick C Chan, Jing Pang & Gerald F Watts. 2023. Lipoprotein(a). Lipoprotein(a) 91 111 .

Emmanuelar O Igweonu-Nwakile, Safina Ali, Salomi Paul, Shreyas Yakkali, Sneha Teresa Selvin, Sonu Thomas, Viktoriya Bikeyeva, Ahmed Abdullah, Aleksandra Radivojevic, Anas A Abu Jad, Anvesh Ravanavena, Chetna Ravindra & Prachi Balani. (2022) A Systematic Review on the Safety and Efficacy of PCSK9 Inhibitors in Lowering Cardiovascular Risks in Patients With Chronic Kidney Disease. Cureus.
Crossref

Kari A. Mäkelä, Jari Jokelainen, Ville Stenbäck, Juha Auvinen, Marjo-Riitta Järvelin, Mikko Tulppo, Juhani Leppäluoto, Sirkka Keinänen-Kiukaanniemi & Karl-Heinz Herzig. (2021) PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy. Journal of Clinical Medicine 10:5, pages 994.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references